Setidegrasib is a quinazoline-linked (4R)-4-hydroxy-L-prolinamide-based PROTAC designed to target and degrade the G12D-mutant KRAS protein. Its structure enables selective recruitment of the mutant protein for proteasomal degradation.
Usually ships within 24 hours.